Status: Recruiting
Metastatic Nasopharyngeal Carcinoma
To evaluaate the efficacy and safety of the regimen incuding Penpulimab, Gemcitabine and Anlotinib in the treatment of metastatic nasopharyngeal carcinoma. Using Progression-Free-Survival as the primary endpoint.
Participants needed: 47
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Chen XiaozhongUpdated: Mar 20, 2025Locations: 1
Eligibility criteria
The participants voluntarily signed an informed consent form. [+9]
ubjects have had another malignancy within 3 years before the first dose, except... [+8]